VCEL

57.5201.27%
KF

Kevin F. McLaughlin

Independent Director

Mr. Kevin F. McLaughlin, M.B.A. is Independent Director of Invivyd, Inc. from May 21, 2024. He served as Director of Combined Therapeutics, Inc. from March 2023. He served as Independent Director of Decibel Therapeutics, Inc. since October 2022 until September 25, 2023. He serves as Training Consultant of John M. Campbell and Company Inc. Mr. McLaughlin served as Senior Vice President, Chief Financial Officer and Treasurer of Acceleron Pharma, Inc., a biotechnology company, from November 2010 to December 2021. He worked in the UK Chemical industry prior to moving into the oil and gas production industry. He has specialized knowledge and experience in water treatment associated with oil and gas production systems. He was Manager of a group of technical specialists for a major Production Chemical Manufacturing company, with additional responsibility for product development, management and application in oil and gas production systems. He has traveled extensively to onshore and offshore locations throughout the Eastern Hemisphere solving water treatment and separation problems. He served as the Chief Financial Officer and Senior Vice President of Qteros, Inc. from October 2009 to 2010. Mr. McLaughlin was co-Founder and Chief Operating Officer at Aptius Education, Inc from 2007 to 2009. From March 1996 to August 1996, he served as the Vice President and Chief Financial Officer of Advanced Techcom, Inc. He served as Vice President of ventures and business support for BP’s chemicals business based in Shanghai, China. From 1996 to 2007, Mr. McLaughlin held several executive positions with PRAECIS Pharmaceuticals, Inc. He served as Treasurer and Senior Vice President of Praecis Pharmaceuticals Inc. since July 1998 and served as its Secretary since January 1997 and Chief Executive Officer since January 2005. Mr. McLaughlin serves as a Director at Stealth Delaware since March 2017 until November 2022. He served as the Chief Operating Officer of Praecis Pharmaceuticals Inc. from September 7, 2004 to January 2005 and also served as its Chief Financial Officer since September 1996 and President since September 7, 2004. He served as Principal Accounting Officer and Executive Vice President of Praecis Pharmaceuticals Inc. From 1980 to 1996, he held senior level financial positions at Computer vision Corporation and its predecessor Prime Computer, Inc., including Vice President, Treasurer and Director of Corporate Planning, where he was directly involved with financial, accounting and Investor Relations management, as well as public and private financing. He has been a Non-Employee Director at Stealth BioTherapeutics Corporated since August 2017. He has served as a Director of Stealth BioTherapeutics Inc., or Stealth Delawaresince March 2017. He has been an Independent Director of Vericel Corporation since January 2015. He served as a Director of Praecis Pharmaceuticals Inc. since January 2005 until 2007. He served as a Director of Aptius Education, Inc. from 2007 to 2009. He has developed and taught courses in oilfield water treatment since 1990. He is a Chartered Chemist, Member of the Royal Society of Chemistry, London, UK and a Member of SPE. He began his career in senior financial roles at Prime Computer and Computervision Corporation. Mr. McLaughlin holds B.S. in physical distribution management, business administration and Accounting from Northeastern University and his MBA from Babson F.W. Olin Graduate School of Business.

Positions